|This Slide: #27 of 100|
Slide #27. Quest Diagnostics — Solstas Lab Partners
Quest Diagnostics (NYSE:DGX)
Solstas Lab Partners
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into a definitive agreement under which Quest will acquire Solstas Lab Partners Group and its subsidiaries (Solstas) for a total transaction value of approximately $570 million. Solstas is a portfolio company of Welsh, Carson, Anderson and Stowe, a private-equity firm specializing in information/business services and healthcare businesses.
Quest Diagnostics provides diagnostic information services. Co.'s diagnostic information segment provides information based on the menu of routine, non-routine and clinical testing and anatomic pathology testing, and other diagnostic information services. Co.'s testing capabilities, includes services for the predisposition, diagnosis, treatment and monitoring of cancers and other diseases, and provides tests in several fields, including endocrinology, immunology, neurology and oncology. Co.'s diagnostic solutions provides risk assessment services for the life insurance industry, as well as provides healthcare organizations and clinicians health information technology solutions.
Quest Diagnostics SEC Filing Email Alerts Service
Open the DGX Page at The Online Investor »
Buy (3.25 out of 4)
(ranked higher than approx. 50% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite